The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

The average price per insulin unit hit a 10-year low in 2024, largely driven by federal actions and voluntary price cuts from drugmakers, according to a Jan. 15 GoodRx report. GoodRx analyzed the ...

Clarivate identifies eleven potential blockbuster and transformative drugs in annual Drugs to Watch report: London, UK Friday, January 10, 2025, 14:00 Hrs [IST] Clarivate Plc, a l ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Drugs for metabolic diseases, vaccines, and cancer therapies feature among new product launches this year that could top $1 ...

In the time since, though, some analysts have said the reaction is overblown, particularly for weight-loss drugmakers like Wegovy, and Ozempic maker Novo Nordisk and Zepbound maker Eli Lilly.

Both Lilly and Novo Nordisk are experiencing unprecedented growth thanks to their weight loss medications. However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema ...

Enter Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the makers behind blockbuster glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are ...

Eli Lilly announced FDA approval of Zepbound as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea. In addition, adults on Zepbound lost an average of 45 ...

Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli Lilly medicine initially developed as a treatment ...